GIOMMONI, ELISA
GIOMMONI, ELISA
Medicina Sperimentale e Clinica
Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy
2022 Caliman, Enrico; Fancelli, Sara; Ottanelli, Carlotta; Mazzoni, Francesca; Paglialunga, Luca; Lavacchi, Daniele; Michelet, Marta Rita Gatta; Giommoni, Elisa; Napolitano, Brunella; Scolari, Federico; Voltolini, Luca; Comin, Camilla Eva; Pillozzi, Serena; Antonuzzo, Lorenzo
Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)
2021 Giommoni, Elisa; Maiello, Evaristo; Vaccaro, Vanja; Rondini, Ermanno; Vivaldi, Caterina; Tortora, Giampaolo; Toppo, Laura; Giordano, Guido; Latiano, Tiziana Pia; Lamperini, Cinzia; Pillozzi, Serena; Boni, Luca; Antonuzzo, Lorenzo; Di Costanzo, Francesco
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience
2021 Lavacchi D.; Roviello G.; Giommoni E.; Dreoni L.; Derio S.; Brugia M.; Amedei A.; Pillozzi S.; Antonuzzo L.
Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
2021 Paderi, Agnese; Giorgione, Roberta; Giommoni, Elisa; Mela, Marinella Micol; Rossi, Virginia; Doni, Laura; Minervini, Andrea; Carini, Marco; Pillozzi, Serena; Antonuzzo, Lorenzo
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis
2021 Paderi A.; Gambale E.; Botteri C.; Giorgione R.; Lavacchi D.; Brugia M.; Mazzoni F.; Giommoni E.; Bormioli S.; Amedei A.; Pillozzi S.; Cerinic M.M.; Antonuzzo L.
Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study
2015 Antonuzzo, Lorenzo; Giommoni, Elisa; Pastorelli, Davide; Latiano, Tiziana; Pavese, Ida; Azzarello, Domenico; Aieta, Michele; Pastina, Ilaria; Di Fabio, Francesca; Bertolini, Alessandro; Corsi, Domenico Cristiano; Mogavero, Selene; Angelini, Valentina; Pazzagli, Mario; Di Costanzo, Francesco
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study
2021 Salvianti, Francesca; Gelmini, Stefania; Mancini, Irene; Pazzagli, Mario; Pillozzi, Serena; Giommoni, Elisa; Brugia, Marco; Di Costanzo, Francesco; Galardi, Francesca; De Luca, Francesca; Castiglione, Francesca; Messerini, Luca; Pinzani, Pamela; Antonuzzo, Lorenzo
Editorial: Redox Potential and Metabolic Behavior in Gastrointestinal Cancers
2022 Biagioni, Alessio; Peri, Sara; Schiavone, Nicola; Giommoni, Elisa; Papucci, Laura
Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients
2021 Giommoni, Elisa; Giorgione, Roberta; Paderi, Agnese; Pellegrini, Elisa; Gambale, Elisabetta; Marini, Andrea; Antonuzzo, Andrea; Marconcini, Riccardo; Roviello, Giandomenico; Matucci-Cerinic, Marco; Capaccioli, David; Pillozzi, Serena; Antonuzzo, Lorenzo
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
2023 Lavacchi, Daniele; Roviello, Giandomenico; Guidolin, Alessia; Romano, Silvia; Venturini, Jacopo; Caliman, Enrico; Vannini, Agnese; Giommoni, Elisa; Pellegrini, Elisa; Brugia, Marco; Pillozzi, Serena; Antonuzzo, Lorenzo
Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification
2014 Meoni, Giulia; Antonuzzo, Lorenzo; Messerini, Luca; Giommoni, Elisa; Muto, Andrea; Petreni, Paolo; Vannini, Agnese; Lunghi, Alice; Molinara, Elena; Di Costanzo, Francesco
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
2023 Reni, M; Giommoni, E; Bergamo, F; Milella, M; Cavanna, L; Di Marco, M C; Spada, M; Cordio, S; Aprile, G; Cardellino, G G; Maiello, E; Bernardini, I; Ghidini, M; Bozzarelli, S; Macchini, M; Orsi, G; De Simone, I; Rulli, Er; Porcu, L; Torri, V; Pinto, C
HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research
2016 Pietrantonio, F; Caporale, M; Morano, F; Scartozzi, M; Gloghini, A; De Vita, F; Giommoni, E; Fornaro, L; Aprile, G; Melisi, D; Berenato, R; Mennitto, A; Volpi, C C; Laterza, M M; Pusceddu, V; Antonuzzo, L; Vasile, E; Ongaro, E; Simionato, F; de Braud, F; Torri, V; Di Bartolomeo, M
hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study.
2012 Lastraioli E; Bencini L; Bianchini E; Romoli MR; Crociani O; Giommoni E; Messerini L; Gasperoni S; Moretti R; Di Costanzo F; Boni L; Arcangeli A.
hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications
2014 Crociani O; Lastraioli E; Boni L; Pillozzi S; Romoli MR; D'Amico M; Stefanini M; Crescioli S; Taddei A; Bencini L; Bernini M; Farsi M; Beghelli S; Scarpa A; Messerini L; Tomezzoli A; Vindigni C; Morgagni P; Saragoni L; Giommoni E; Gasperoni S; Di Costanzo F; Roviello F; De Manzoni G; Bechi P; Arcangeli A.
Immune-related adverse events in oncological patients treated with immune checkpoint inhibitors
2023 Elisa Giommoni
Isoforms of the orphan nuclear receptor COUP-TFII differentially modulate pancreatic cancer progression
2022 Polvani, S; Pepe, S; Tempesti, S; Tarocchi, M; Marroncini, G; Bencini, L; Ceni, E; Mello, T; Picariello, L; Simeone, I; Grappone, C; Dragoni, G; Antonuzzo, L; Giommoni, E; Milani, S; Galli, A
Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine
2023 Di Costanzo, Francesco; Di Costanzo, Federica; Antonuzzo, Lorenzo; Mazza, Ernesto; Giommoni, Elisa
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect
2017 Antonuzzo, Lorenzo; Lunghi, Alice; Petreni, Paolo; Brugia, Marco; Laffi, Alice; Giommoni, Elisa; Mela, Marinella M; Mazzoni, Francesca; Balestri, Vanni; Costanzo, Francesco Di
Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: A phase II study
2007 Neri, B.; Pantaleo, P.; Giommoni, E.; Grifoni, R.; Paoletti, C.; Rotella, V.; Pantalone, D.; Taddei, A.; Mercatelli, A.; Tonelli, P.
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy | 2022 | Caliman, Enrico; Fancelli, Sara; Ottanelli, Carlotta; Mazzoni, Francesca; Paglialunga, Luca; Lavacchi, Daniele; Michelet, Marta Rita Gatta; Giommoni, Elisa; Napolitano, Brunella; Scolari, Federico; Voltolini, Luca; Comin, Camilla Eva; Pillozzi, Serena; Antonuzzo, Lorenzo | |
| Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study) | 2021 | Giommoni, Elisa; Maiello, Evaristo; Vaccaro, Vanja; Rondini, Ermanno; Vivaldi, Caterina; Tortora, Giampaolo; Toppo, Laura; Giordano, Guido; Latiano, Tiziana Pia; Lamperini, Cinzia; Pillozzi, Serena; Boni, Luca; Antonuzzo, Lorenzo; Di Costanzo, Francesco | |
| Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience | 2021 | Lavacchi D.; Roviello G.; Giommoni E.; Dreoni L.; Derio S.; Brugia M.; Amedei A.; Pillozzi S.; Antonuzzo L. | |
| Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors | 2021 | Paderi, Agnese; Giorgione, Roberta; Giommoni, Elisa; Mela, Marinella Micol; Rossi, Virginia; Doni, Laura; Minervini, Andrea; Carini, Marco; Pillozzi, Serena; Antonuzzo, Lorenzo | |
| Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis | 2021 | Paderi A.; Gambale E.; Botteri C.; Giorgione R.; Lavacchi D.; Brugia M.; Mazzoni F.; Giommoni E.; Bormioli S.; Amedei A.; Pillozzi S.; Cerinic M.M.; Antonuzzo L. | |
| Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study | 2015 | Antonuzzo, Lorenzo; Giommoni, Elisa; Pastorelli, Davide; Latiano, Tiziana; Pavese, Ida; Azzarello, Domenico; Aieta, Michele; Pastina, Ilaria; Di Fabio, Francesca; Bertolini, Alessandro; Corsi, Domenico Cristiano; Mogavero, Selene; Angelini, Valentina; Pazzagli, Mario; Di Costanzo, Francesco | |
| Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study | 2021 | Salvianti, Francesca; Gelmini, Stefania; Mancini, Irene; Pazzagli, Mario; Pillozzi, Serena; Giommoni, Elisa; Brugia, Marco; Di Costanzo, Francesco; Galardi, Francesca; De Luca, Francesca; Castiglione, Francesca; Messerini, Luca; Pinzani, Pamela; Antonuzzo, Lorenzo | |
| Editorial: Redox Potential and Metabolic Behavior in Gastrointestinal Cancers | 2022 | Biagioni, Alessio; Peri, Sara; Schiavone, Nicola; Giommoni, Elisa; Papucci, Laura | |
| Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients | 2021 | Giommoni, Elisa; Giorgione, Roberta; Paderi, Agnese; Pellegrini, Elisa; Gambale, Elisabetta; Marini, Andrea; Antonuzzo, Andrea; Marconcini, Riccardo; Roviello, Giandomenico; Matucci-Cerinic, Marco; Capaccioli, David; Pillozzi, Serena; Antonuzzo, Lorenzo | |
| Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer | 2023 | Lavacchi, Daniele; Roviello, Giandomenico; Guidolin, Alessia; Romano, Silvia; Venturini, Jacopo; Caliman, Enrico; Vannini, Agnese; Giommoni, Elisa; Pellegrini, Elisa; Brugia, Marco; Pillozzi, Serena; Antonuzzo, Lorenzo | |
| Gallbladder neuroendocrine neoplasm: a case report and critical evaluation of WHO classification | 2014 | Meoni, Giulia; Antonuzzo, Lorenzo; Messerini, Luca; Giommoni, Elisa; Muto, Andrea; Petreni, Paolo; Vannini, Agnese; Lunghi, Alice; Molinara, Elena; Di Costanzo, Francesco | |
| Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey | 2023 | Reni, M; Giommoni, E; Bergamo, F; Milella, M; Cavanna, L; Di Marco, M C; Spada, M; Cordio, S; Aprile, G; Cardellino, G G; Maiello, E; Bernardini, I; Ghidini, M; Bozzarelli, S; Macchini, M; Orsi, G; De Simone, I; Rulli, Er; Porcu, L; Torri, V; Pinto, C | |
| HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research | 2016 | Pietrantonio, F; Caporale, M; Morano, F; Scartozzi, M; Gloghini, A; De Vita, F; Giommoni, E; Fornaro, L; Aprile, G; Melisi, D; Berenato, R; Mennitto, A; Volpi, C C; Laterza, M M; Pusceddu, V; Antonuzzo, L; Vasile, E; Ongaro, E; Simionato, F; de Braud, F; Torri, V; Di Bartolomeo, M | |
| hERG1 Channels and Glut-1 as Independent Prognostic Indicators of Worse Outcome in Stage I and II Colorectal Cancer: A Pilot Study. | 2012 | Lastraioli E; Bencini L; Bianchini E; Romoli MR; Crociani O; Giommoni E; Messerini L; Gasperoni S; Moretti R; Di Costanzo F; Boni L; Arcangeli A. | |
| hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications | 2014 | Crociani O; Lastraioli E; Boni L; Pillozzi S; Romoli MR; D'Amico M; Stefanini M; Crescioli S; Taddei A; Bencini L; Bernini M; Farsi M; Beghelli S; Scarpa A; Messerini L; Tomezzoli A; Vindigni C; Morgagni P; Saragoni L; Giommoni E; Gasperoni S; Di Costanzo F; Roviello F; De Manzoni G; Bechi P; Arcangeli A. | |
| Immune-related adverse events in oncological patients treated with immune checkpoint inhibitors | 2023 | Elisa Giommoni | |
| Isoforms of the orphan nuclear receptor COUP-TFII differentially modulate pancreatic cancer progression | 2022 | Polvani, S; Pepe, S; Tempesti, S; Tarocchi, M; Marroncini, G; Bencini, L; Ceni, E; Mello, T; Picariello, L; Simeone, I; Grappone, C; Dragoni, G; Antonuzzo, L; Giommoni, E; Milani, S; Galli, A | |
| Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine | 2023 | Di Costanzo, Francesco; Di Costanzo, Federica; Antonuzzo, Lorenzo; Mazza, Ernesto; Giommoni, Elisa | |
| Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect | 2017 | Antonuzzo, Lorenzo; Lunghi, Alice; Petreni, Paolo; Brugia, Marco; Laffi, Alice; Giommoni, Elisa; Mela, Marinella M; Mazzoni, Francesca; Balestri, Vanni; Costanzo, Francesco Di | |
| Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: A phase II study | 2007 | Neri, B.; Pantaleo, P.; Giommoni, E.; Grifoni, R.; Paoletti, C.; Rotella, V.; Pantalone, D.; Taddei, A.; Mercatelli, A.; Tonelli, P. |